BEST3-Mediated MEKK2/3 Activation: A Novel Therapeutic Target in Aortopathies

Research output: Contribution to journalEditorial

1 Scopus citations
Original languageEnglish
Pages (from-to)607-609
Number of pages3
JournalCirculation
Volume148
Issue number7
DOIs
StatePublished - Aug 15 2023

Bibliographical note

Funding Information:
The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R35HL155649) and the American Heart Association Merit Award (23MERIT1036341). The content in this editorial is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding

The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R35HL155649) and the American Heart Association Merit Award (23MERIT1036341). The content in this editorial is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FundersFunder number
National Institutes of Health (NIH)R35HL155649
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
American the American Heart Association23MERIT1036341
American the American Heart Association

    Keywords

    • Editorials
    • aneurysm
    • angiotensins
    • aorta
    • dissection
    • myocytes, smooth muscle
    • vascular diseases

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Physiology (medical)

    Fingerprint

    Dive into the research topics of 'BEST3-Mediated MEKK2/3 Activation: A Novel Therapeutic Target in Aortopathies'. Together they form a unique fingerprint.

    Cite this